Evidence-Based Pathways & Guidelines
Reficio Evidence-Based Clinical Pathway
From diagnostic laboratory finding to clinical interpretation, verified WHO and National guideline matching, treatment eligibility, medication safety rules, and specialist referral.
High-Risk Human Papillomavirus (HPV) DNA Detected (Genotype 16)
| Investigation | Reported Result | Reference Range | Status Flag |
|---|---|---|---|
| High-Risk HPV DNA Real-Time PCR | Positive (Ct 24.2) | Negative / Not Detected | POSITIVE |
Molecular detection of HPV Genotype 16 DNA indicates high-risk oncogenic viral presence in cervical epithelial cells. This is an evidence-based screen-positive result requiring clinical triage, not an automatic cancer diagnosis.
Colposcopy & Transformation Zone Visual Assessment
Evaluates transformation zone visibility and identifies acetowhite epithelial lesions for guided biopsy or immediate thermal ablation eligibility.
Follow-Up High-Risk HPV DNA Test at 12 Months
Confirms clearance versus persistent oncogenic viral carriage.
WHO guideline for screening and treatment of cervical pre-cancer lesions, 2nd Edition
Screen-and-treat strategy with thermal ablation or LLETZ excisional therapy depending upon transformation zone visibility.
View Official GuidelineICMR Guidelines for Cervical Cancer Screening & Management in India
Link to community health center / district hospital for colposcopy triage and single-visit cryo/thermal ablation.
View Official GuidelineStandard Treatment Protocol: In the absence of invasive carcinoma on colposcopic assessment, thermal ablation or Large Loop Excision of the Transformation Zone (LLETZ) is indicated.
- Ablative therapy is contraindicated if lesions extend > 2mm into the endocervical canal or if invasive carcinoma is suspected.
- Post-coital or irregular intermenstrual vaginal bleeding
- Persistent foul-smelling vaginal discharge
- Pelvic pain or palpable cervical lesion on examination
Referral to Gynecologist / Gynae-Oncologist for Colposcopy and Cervical Triage
Timeline: Clinical triage within 4 weeks; repeat HPV DNA testing at 12 months